Cerula Care raises $3.7M seed round to support cancer patients' mental health between appointments, selling directly to ...

Biogen is turning to Royalty Pharma for some cash in exchange for rights to a lupus program, the companies announced ...

After quickly enrolling its pivotal trial and recruiting more patients with a rare muscle disease than anticipated, Abcuro ...

AnaptysBio trumpeted a Phase 2b success in rheumatoid arthritis Wednesday morning after a similar program from Eli Lilly was discontinued late last year.

Ab­b­Vie and Xilio Ther­a­peu­tics are part­ner­ing to make “masked” T cell en­gagers, which they hope will be safer than cur­rent­ly avail­able op­tions.

Odyssey layoffs, GSK relocates vaccine R&D, Aligos raises $105M, Terrain Bio launches, Gates Foundation backs antibiotics research, Neuphoria gets Merck milestone ...

CMO Dietmar Berger leads Gilead's R&D efforts with 54 clinical programs, anticipating Sunlenca's HIV PrEP launch & touting no ...

Spring­Works Ther­a­peu­tics, a biotech po­ten­tial­ly on the verge of be­ing ac­quired, won its sec­ond FDA ap­proval. Get ...

FDA grants priority review for Biohaven's troriluzole for spinocerebellar ataxia after real-world data submission. Decision ...

Travere Therapeutics said Tuesday it plans to ask the FDA for approval of its kidney drug Filspari in a rare condition known ...

Chinese API manufacturers Wuhu Nuowei Chemistry and Chengdu Innovation Pharmaceutical have been placed on US import alert ...

Leaked Pfizer Phase 1 trial shows mevrometostat plus Xtandi reduced prostate cancer progression risk by 49%. Data sparked ...